Stephen G. Sawada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stephen G. Sawada has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Harvey Feigenbaum
Indiana University School of Medicine, IU Health Methodist Hospital, Indianapolis, IN, 46202, USA
12 shared publicationsJothiharan Mahenthiran
7 shared publicationsIrmina Gradus-Pizlo
Krannert Institute of Cardiology and Indiana University School of Medicine , 1801 North Senate Blvd., M.P.C. II, Suite D4082, Indianapolis, IN 46202 , USA
4 shared publicationsIrmina Gradus‐Pizlo
Department of Medicine of Indiana University Medical Center and the Krannert Institute of Cardiology Indianapolis Indiana
4 shared publicationsNaomi Fineberg
Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana
4 shared publicationsMasoor Kamalesh
Krannert Institute of Cardiology and Indiana University School of Medicine , 1801 North Senate Blvd., M.P.C. II, Suite D4082, Indianapolis, IN 46202 , USA
3 shared publications
Latest Publications
- 3 May 2019
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 35 (9) , 1651-1659
Low dose wall motion score predicts the short and long-term benefit of surgical revascularization in patients with ischemic left ventricular dysfunction
We investigated the influence of the extent of viability using low dose dobutamine wall motion score index (WMS) on the survival benefit of surgical revascularization (CABG) versus medical therapy. In the STICH trial, viability assessment was not helpful in determining the benefit of CABG. However, the extent of viable myocardium with contractile function was not assessed in the trial. Dobutamine echocardiography was performed in 250 patients with ischemic left ventricular dysfunction (125-medically treated, 125-CABG). The mean ejection fraction (EF) was 32% in both groups. WMS during low dose dobutamine infusion was used to classify patients into groups with extensive (WMS < 2.00), intermediate (WMS 2.00–2.49), and limited (WMS ≥ 2.50) viability. Survival free of cardiac death was assessed at 2 years and for the complete duration of follow-up. There were 44 (35.2%) and 67 (53.6%) cardiac deaths in the revascularized and medically treated patients respectively (follow-up of 5.7 ± 5.8 years). Revascularized and medically treated patients with extensive viability had similar 2-year survival (p = 0.567) but revascularized patients had improved long-term survival (p = 0.0001). In those with intermediate viability, revascularization improved both 2 year (p = 0.014) and long-term survival (p = 0.0001). In patients with limited viability, 2-year survival was worse in revascularized patients (p = 0.04) and long-term survival was similar (p = 0 .25) in revascularized and medically treated groups. Patients with extensive and intermediate amounts of viability have improved survival with CABG but those with limited viability have poorer short-term outcome and no long-term benefit.
- 3 May 2019
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 35 (9) , 1651-1659
Low dose wall motion score predicts the short and long-term benefit of surgical revascularization in patients with ischemic left ventricular dysfunction
We investigated the influence of the extent of viability using low dose dobutamine wall motion score index (WMS) on the survival benefit of surgical revascularization (CABG) versus medical therapy. In the STICH trial, viability assessment was not helpful in determining the benefit of CABG. However, the extent of viable myocardium with contractile function was not assessed in the trial. Dobutamine echocardiography was performed in 250 patients with ischemic left ventricular dysfunction (125-medically treated, 125-CABG). The mean ejection fraction (EF) was 32% in both groups. WMS during low dose dobutamine infusion was used to classify patients into groups with extensive (WMS < 2.00), intermediate (WMS 2.00–2.49), and limited (WMS ≥ 2.50) viability. Survival free of cardiac death was assessed at 2 years and for the complete duration of follow-up. There were 44 (35.2%) and 67 (53.6%) cardiac deaths in the revascularized and medically treated patients respectively (follow-up of 5.7 ± 5.8 years). Revascularized and medically treated patients with extensive viability had similar 2-year survival (p = 0.567) but revascularized patients had improved long-term survival (p = 0.0001). In those with intermediate viability, revascularization improved both 2 year (p = 0.014) and long-term survival (p = 0.0001). In patients with limited viability, 2-year survival was worse in revascularized patients (p = 0.04) and long-term survival was similar (p = 0 .25) in revascularized and medically treated groups. Patients with extensive and intermediate amounts of viability have improved survival with CABG but those with limited viability have poorer short-term outcome and no long-term benefit.
- 8 April 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 111 (11) , 1593-1597
Improving Prediction of Outcomes in African Americans With Normal Stress Echocardiograms Using a Risk Scoring System
- 8 April 2013
- Published by Elsevier in The American Journal of Cardiology
- Vol. 111 (11) , 1593-1597
Improving Prediction of Outcomes in African Americans With Normal Stress Echocardiograms Using a Risk Scoring System
- 8 January 2013
- Published by Wiley in Echocardiography
- Vol. 30 (1) , 8
Continuing Medical Education Activity in Echocardiography
- 8 January 2013
- Published by Wiley in Echocardiography
- Vol. 30 (1) , 8
Continuing Medical Education Activity in Echocardiography
- 7 September 2012
- Published by Wiley in Echocardiography
- Vol. 30 (1) , 9-16
Frequency, Time Course, and Possible Causes of Right Ventricular Systolic Dysfunction after Cardiac Transplantation: A Single Center Experience
The frequency and causes of right ventricular (RV) systolic dysfunction early after cardiac transplantation are not well defined. We investigated the prevalence and causes of RV dysfunction in 27 heart transplant recipients, as measured by lateral tricuspid annular plane excursion (TAPSE) and fractional area change (FAC) at a mean of 15 ± 11 days after transplant. Tissue Doppler imaging was used to assess systolic time velocity integral (TVI) of the RV basal free wall. A subset of 22 patients had follow-up TAPSE measurement at 406 ± 121 days. RV systolic dysfunction, defined as TAPSE > 2 standard deviation (SD) below values in a control group, was present in 100% (27/27) of patients (P < 0.05). FAC was also significantly lower in patients compared with controls (P < 0.0001). TVI confirmed the presence of RV dysfunction in all 16 patients with both TAPSE and TVI (P < 0.05). Ischemic time (P = 0.017) and posttransplant tricuspid regurgitation (P = 0.024) were independent predictors of early RV dysfunction (r = 0.753). On follow-up, RV function improved in 15 of 22 patients but all patients remained with TAPSE > 2 SD below controls. This study showed that 100% of patients had reduced RV function early after transplant. Two thirds of patients had partial recovery of RV function during the first year. In all patients, however, RV function remained significantly lower than in controls.
- 7 September 2012
- Published by Wiley in Echocardiography
- Vol. 30 (1) , 9-16
Frequency, Time Course, and Possible Causes of Right Ventricular Systolic Dysfunction after Cardiac Transplantation: A Single Center Experience
The frequency and causes of right ventricular (RV) systolic dysfunction early after cardiac transplantation are not well defined. We investigated the prevalence and causes of RV dysfunction in 27 heart transplant recipients, as measured by lateral tricuspid annular plane excursion (TAPSE) and fractional area change (FAC) at a mean of 15 ± 11 days after transplant. Tissue Doppler imaging was used to assess systolic time velocity integral (TVI) of the RV basal free wall. A subset of 22 patients had follow-up TAPSE measurement at 406 ± 121 days. RV systolic dysfunction, defined as TAPSE > 2 standard deviation (SD) below values in a control group, was present in 100% (27/27) of patients (P < 0.05). FAC was also significantly lower in patients compared with controls (P < 0.0001). TVI confirmed the presence of RV dysfunction in all 16 patients with both TAPSE and TVI (P < 0.05). Ischemic time (P = 0.017) and posttransplant tricuspid regurgitation (P = 0.024) were independent predictors of early RV dysfunction (r = 0.753). On follow-up, RV function improved in 15 of 22 patients but all patients remained with TAPSE > 2 SD below controls. This study showed that 100% of patients had reduced RV function early after transplant. Two thirds of patients had partial recovery of RV function during the first year. In all patients, however, RV function remained significantly lower than in controls.
- Open Access
- 5 September 2011
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 12 (10) , 807-808
Geometry or function for the prediction of prognosis following revascularization in ischaemic cardiomyopathy: beyond the ejection fraction: reply
We appreciate the insightful comments of Shah regarding geometry and function for prognostic assessment in ischaemic cardiomyopathy.1 We agree with him about the prognostic importance of end-systolic volume (ESV). As Shah points out, in our investigation, there was a trend towards larger baseline ESV before revascularization in patients with cardiac death (P= 0.052).2 For the purposes of responding to Shah's query, we assessed the prognostic value of ESV following revascularization. Larger ESV on follow-up echocardiography was a univariate predictor (P= 0.003) of cardiac death. However, neither baseline nor follow-up ESV was an independent predictor of outcome on multivariate analysis. Wall motion scores, ejection fraction (EF) improvement, and digoxin use in follow-up remained as the only independent predictors of outcome.
- 5 September 2011
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 12 (10) , 807-808
Open AccessGeometry or function for the prediction of prognosis following revascularization in ischaemic cardiomyopathy: beyond the ejection fraction: reply
We appreciate the insightful comments of Shah regarding geometry and function for prognostic assessment in ischaemic cardiomyopathy.1 We agree with him about the prognostic importance of end-systolic volume (ESV). As Shah points out, in our investigation, there was a trend towards larger baseline ESV before revascularization in patients with cardiac death (P= 0.052).2 For the purposes of responding to Shah's query, we assessed the prognostic value of ESV following revascularization. Larger ESV on follow-up echocardiography was a univariate predictor (P= 0.003) of cardiac death. However, neither baseline nor follow-up ESV was an independent predictor of outcome on multivariate analysis. Wall motion scores, ejection fraction (EF) improvement, and digoxin use in follow-up remained as the only independent predictors of outcome.
- Open Access
- 5 May 2011
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 12 (6) , 454-460
Effect of improvement in left ventricular ejection fraction on long-term survival in revascularized patients with ischaemic left ventricular systolic dysfunction
The importance of improvement in the ejection fraction to the prognosis of revascularized patients with ischaemic left ventricular (LV) dysfunction is uncertain. Eighty-seven patients with ischaemic LV dysfunction (mean ejection fraction 29 ± 8% by biplane Simpson's) had dobutamine echocardiography before revascularization (coronary bypass graft surgery-81, percutaneous intervention-6). Follow-up echocardiograms were performed a mean of 4.8 ± 6.2 months after revascularization. An 8% increase in the ejection fraction was considered significant (two times the inter-observer difference of 3.7%). Patients were followed for cardiac death. During a mean follow-up of 5.2 ± 3.9 years, there were 20 (23%) cardiac deaths. Class 3/4 heart failure, increasing low-dose wall motion score, increasing % non-viable myocardium, and digoxin use in follow-up were univariate predictors of death. Beta-blocker use, ejection fraction improvement, angina, aspirin use, and increasing fractional shortening were univariate predictors of survival. Ejection fraction improvement [P= 0.02, hazard ratio (HR) = 0.26], digoxin use in follow-up (P= 0.006, HR = 5.85), and low-dose wall motion score (P= 0.017, HR = 4.78) were independent predictors of outcome. In step-wise analysis, low-dose wall motion score added incremental prognostic value to ejection fraction improvement (P= 0.003), and digoxin use in follow-up (P= 0.003) added incremental value to a low-dose score and ejection fraction improvement. Ejection fraction improvement is an independent predictor of long-term outcome in revascularized patients but viability (low-dose wall motion score) and digoxin use in follow-up are also independent predictors and add incremental prognostic value to ejection fraction improvement.
- 5 May 2011
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 12 (6) , 454-460
Open AccessEffect of improvement in left ventricular ejection fraction on long-term survival in revascularized patients with ischaemic left ventricular systolic dysfunction
The importance of improvement in the ejection fraction to the prognosis of revascularized patients with ischaemic left ventricular (LV) dysfunction is uncertain. Eighty-seven patients with ischaemic LV dysfunction (mean ejection fraction 29 ± 8% by biplane Simpson's) had dobutamine echocardiography before revascularization (coronary bypass graft surgery-81, percutaneous intervention-6). Follow-up echocardiograms were performed a mean of 4.8 ± 6.2 months after revascularization. An 8% increase in the ejection fraction was considered significant (two times the inter-observer difference of 3.7%). Patients were followed for cardiac death. During a mean follow-up of 5.2 ± 3.9 years, there were 20 (23%) cardiac deaths. Class 3/4 heart failure, increasing low-dose wall motion score, increasing % non-viable myocardium, and digoxin use in follow-up were univariate predictors of death. Beta-blocker use, ejection fraction improvement, angina, aspirin use, and increasing fractional shortening were univariate predictors of survival. Ejection fraction improvement [P= 0.02, hazard ratio (HR) = 0.26], digoxin use in follow-up (P= 0.006, HR = 5.85), and low-dose wall motion score (P= 0.017, HR = 4.78) were independent predictors of outcome. In step-wise analysis, low-dose wall motion score added incremental prognostic value to ejection fraction improvement (P= 0.003), and digoxin use in follow-up (P= 0.003) added incremental value to a low-dose score and ejection fraction improvement. Ejection fraction improvement is an independent predictor of long-term outcome in revascularized patients but viability (low-dose wall motion score) and digoxin use in follow-up are also independent predictors and add incremental prognostic value to ejection fraction improvement.
- 1 July 2010
- Published by Elsevier in The American Journal of Cardiology
- Vol. 106 (2) , 187-192
Effect of Revascularization on Long-Term Survival in Patients With Ischemic Left Ventricular Dysfunction and a Wide Range of Viability
- 1 July 2010
- Published by Elsevier in The American Journal of Cardiology
- Vol. 106 (2) , 187-192
Effect of Revascularization on Long-Term Survival in Patients With Ischemic Left Ventricular Dysfunction and a Wide Range of Viability
- Open Access
- 16 July 2009
- Published by Wiley in Clinical Cardiology
- Vol. 32 (7) , 403-409
Wall Motion Abnormalities with Low‐Dose Dobutamine Predict a High Risk of Cardiac Death in Medically Treated Patients with Ischemic Cardiomyopathy
Background Severe and extensive coronary artery disease is the underlying cause of stress-induced wall motion abnormalities (SWMA) with low-dose (10 µg/kg/min) dobutamine suggesting that these abnormalities may identify those with poor outcome. Hypothesis We assessed the prognostic value of low-dose SWMA in medically treated patients with ischemic cardiomyopathy. Methods Low- and peak-dose dobutamine echocardiography was performed in 235 patients with ischemic cardiomyopathy (ejection fraction 31% ± 8%) who were treated with medical therapy. The survival of patients with low-dose SWMA (n = 33) was compared with the survival of patients without ischemia (n = 85) and those with peak-dose SWMA (n = 117). Results There were 123 cardiac deaths (52%) during follow-up of 4.1 ± 3.3 years. Multivariate predictors of cardiac death were age (p = 0.002, hazard ratio [HR]: 1.03), diabetes (p = 0.028, HR: 1.54), New York Heart Association (NYHA) class III, IV heart failure (p = 0.001, HR: 1.94), the presence of peak dose SWMA (p < 0.001, HR: 2.59), and low-dose SWMA (p = 0.005, HR: 2.28). Survival of patients without ischemia was significantly better than those with peak-dose SWMA (p < 0.0001) and those with low-dose SWMA (p = 0.001). The survival of patients with low-dose SWMA was the same as those with peak-dose SWMA (p = 0.89). Conclusions Low-dose SWMA is an independent predictor of cardiac mortality in medically treated patients with ischemic cardiomyopathy. Patients with low-dose SWMA are at equivalent risk to those with peak-dose SWMA. Copyright
- 16 July 2009
- Published by Wiley in Clinical Cardiology
- Vol. 32 (7) , 403-409
Open AccessWall Motion Abnormalities with Low‐Dose Dobutamine Predict a High Risk of Cardiac Death in Medically Treated Patients with Ischemic Cardiomyopathy
Background Severe and extensive coronary artery disease is the underlying cause of stress-induced wall motion abnormalities (SWMA) with low-dose (10 µg/kg/min) dobutamine suggesting that these abnormalities may identify those with poor outcome. Hypothesis We assessed the prognostic value of low-dose SWMA in medically treated patients with ischemic cardiomyopathy. Methods Low- and peak-dose dobutamine echocardiography was performed in 235 patients with ischemic cardiomyopathy (ejection fraction 31% ± 8%) who were treated with medical therapy. The survival of patients with low-dose SWMA (n = 33) was compared with the survival of patients without ischemia (n = 85) and those with peak-dose SWMA (n = 117). Results There were 123 cardiac deaths (52%) during follow-up of 4.1 ± 3.3 years. Multivariate predictors of cardiac death were age (p = 0.002, hazard ratio [HR]: 1.03), diabetes (p = 0.028, HR: 1.54), New York Heart Association (NYHA) class III, IV heart failure (p = 0.001, HR: 1.94), the presence of peak dose SWMA (p < 0.001, HR: 2.59), and low-dose SWMA (p = 0.005, HR: 2.28). Survival of patients without ischemia was significantly better than those with peak-dose SWMA (p < 0.0001) and those with low-dose SWMA (p = 0.001). The survival of patients with low-dose SWMA was the same as those with peak-dose SWMA (p = 0.89). Conclusions Low-dose SWMA is an independent predictor of cardiac mortality in medically treated patients with ischemic cardiomyopathy. Patients with low-dose SWMA are at equivalent risk to those with peak-dose SWMA. Copyright
- 27 April 2009
- Published by Wiley in Echocardiography
- Vol. 26 (5) , 558-566
Clinical Assessment and Rest and Stress Echocardiography for Prediction of Long‐Term Prognosis in African Americans with Known or Suspected Coronary Artery Disease
Background: There is limited information on noninvasive risk stratification of African Americans, a high‐risk group for cardiovascular events. We investigated the value of clinical assessment and echocardiography for the prediction of a long‐term prognosis in African Americans. Methods: Dobutamine echocardiography was performed in 324 African Americans. Two‐dimensional measurements were performed at rest, and rest and stress wall motion was assessed. A retrospective follow‐up was conducted for cardiac events: myocardial infarction (MI) or cardiac death (CD). Results: The mean age was 59 ± 12 years, and 83% of patients had hypertension. The follow‐up was obtained in 318 (98%) patients for a mean of 5.3 years. The events occurred in 107 (33%) subjects. The independent predictors of events were history of MI (P = 0.001, risk ratio [RR] 2.04), ischemia (P = 0.007, RR 1.97), fractional shortening (P = 0.033, RR 0.08), and left atrial (LA) dimension (P = 0.034, RR 1.39). An LA size of 3.6 cm and a fractional shortening of 0.30 were the best cutoff values for the prediction of events. Prior MI, ischemia, LA size >3.6 cm, and fractional shortening
- 27 April 2009
- Published by Wiley in Echocardiography
- Vol. 26 (5) , 558-566
Clinical Assessment and Rest and Stress Echocardiography for Prediction of Long‐Term Prognosis in African Americans with Known or Suspected Coronary Artery Disease
Background: There is limited information on noninvasive risk stratification of African Americans, a high‐risk group for cardiovascular events. We investigated the value of clinical assessment and echocardiography for the prediction of a long‐term prognosis in African Americans. Methods: Dobutamine echocardiography was performed in 324 African Americans. Two‐dimensional measurements were performed at rest, and rest and stress wall motion was assessed. A retrospective follow‐up was conducted for cardiac events: myocardial infarction (MI) or cardiac death (CD). Results: The mean age was 59 ± 12 years, and 83% of patients had hypertension. The follow‐up was obtained in 318 (98%) patients for a mean of 5.3 years. The events occurred in 107 (33%) subjects. The independent predictors of events were history of MI (P = 0.001, risk ratio [RR] 2.04), ischemia (P = 0.007, RR 1.97), fractional shortening (P = 0.033, RR 0.08), and left atrial (LA) dimension (P = 0.034, RR 1.39). An LA size of 3.6 cm and a fractional shortening of 0.30 were the best cutoff values for the prediction of events. Prior MI, ischemia, LA size >3.6 cm, and fractional shortening
- Open Access
- 7 February 2009
- Published by Springer Nature in Cardiovascular Ultrasound
- Vol. 7 (1) , 5
Evaluation of the anti-ischemic effects of D-ribose during dobutamine stress echocardiography: a pilot study
D-Ribose, a pentose sugar, has shown to improve myocardial high-energy phosphate stores depleted by ischemia. This study investigated the ability of D-Ribose with low dose dobutamine to improve the contractile response of viable myocardium to dobutamine and to assess the efficacy of D-ribose in reducing stress-induced ischemia. Twenty-six patients with ischemic cardiomyopathy completed a two-day, randomized, double blind crossover trial comparing the effects of D-Ribose and placebo on regional wall motion. On the first study day, either D-Ribose or placebo was infused for 4.5 hours. Low (5 and 10 μ/kg/min) and subsequently, high (up to 50 μ/kg/min) dose dobutamine echocardiography was then performed. On the second study day, patients crossed over to the alternative article for a similar 4.5 hours infusion time period and underwent a similar evaluation. The wall motion response during low dose dobutamine was the same with D-Ribose and placebo in 77% of segments (203/263, Kappa = 0.37). In segments with discordant responses, more segments improved with D-Ribose than with placebo (41 vs. 19 segments, p = 0.006). With high dose dobutamine infusion, the wall motion response (ischemia vs. no ischemia) was the same with D-Ribose and placebo in 83% of interpretable segments (301/363, kappa = 0.244). In segments with discordant responses, there were more ischemic segments with placebo compared to D-Ribose (36 vs. 26, p = 0.253). Nineteen patients developed ischemia during the dobutamine and placebo infusion and 13 patients had ischemia during dobutamine and D-ribose infusion (p = 0.109). D-Ribose improved contractile responses to dobutamine in viable myocardium with resting dysfunction but had no significant effect in reducing the frequency of stress-induced wall motion abnormalities.
- 7 February 2009
- Published by Springer Nature in Cardiovascular Ultrasound
- Vol. 7 (1) , 5
Open AccessEvaluation of the anti-ischemic effects of D-ribose during dobutamine stress echocardiography: a pilot study
D-Ribose, a pentose sugar, has shown to improve myocardial high-energy phosphate stores depleted by ischemia. This study investigated the ability of D-Ribose with low dose dobutamine to improve the contractile response of viable myocardium to dobutamine and to assess the efficacy of D-ribose in reducing stress-induced ischemia. Twenty-six patients with ischemic cardiomyopathy completed a two-day, randomized, double blind crossover trial comparing the effects of D-Ribose and placebo on regional wall motion. On the first study day, either D-Ribose or placebo was infused for 4.5 hours. Low (5 and 10 μ/kg/min) and subsequently, high (up to 50 μ/kg/min) dose dobutamine echocardiography was then performed. On the second study day, patients crossed over to the alternative article for a similar 4.5 hours infusion time period and underwent a similar evaluation. The wall motion response during low dose dobutamine was the same with D-Ribose and placebo in 77% of segments (203/263, Kappa = 0.37). In segments with discordant responses, more segments improved with D-Ribose than with placebo (41 vs. 19 segments, p = 0.006). With high dose dobutamine infusion, the wall motion response (ischemia vs. no ischemia) was the same with D-Ribose and placebo in 83% of interpretable segments (301/363, kappa = 0.244). In segments with discordant responses, there were more ischemic segments with placebo compared to D-Ribose (36 vs. 26, p = 0.253). Nineteen patients developed ischemia during the dobutamine and placebo infusion and 13 patients had ischemia during dobutamine and D-ribose infusion (p = 0.109). D-Ribose improved contractile responses to dobutamine in viable myocardium with resting dysfunction but had no significant effect in reducing the frequency of stress-induced wall motion abnormalities.